

Angelina Sacchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5551238/publications.pdf>

Version: 2024-02-01

32
papers

2,120
citations

361413

20
h-index

414414

32
g-index

32
all docs

32
docs citations

32
times ranked

2155
citing authors

#	ARTICLE	IF	CITATIONS
1	Enhancement of tumor necrosis factor β antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). <i>Nature Biotechnology</i> , 2000, 18, 1185-1190.	17.5	403
2	Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. <i>Cancer Research</i> , 2002, 62, 867-74.	0.9	217
3	Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. <i>Journal of Clinical Investigation</i> , 2002, 110, 475-482.	8.2	206
4	Structure-Activity Relationships of Linear and Cyclic Peptides Containing the NGR Tumor-homing Motif. <i>Journal of Biological Chemistry</i> , 2002, 277, 47891-47897.	3.4	159
5	Synergistic Antitumor Activity of Cisplatin, Paclitaxel, and Gemcitabine with Tumor Vasculature-Targeted Tumor Necrosis Factor β . <i>Clinical Cancer Research</i> , 2006, 12, 175-182.	7.0	141
6	Coupling Tumor Necrosis Factor β with α V Integrin Ligands Improves Its Antineoplastic Activity. <i>Cancer Research</i> , 2004, 64, 565-571.	0.9	134
7	Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. <i>Journal of Clinical Investigation</i> , 2002, 110, 475-482.	8.2	111
8	Targeted Delivery of IFN γ to Tumor Vessels Uncouples Antitumor from Counterregulatory Mechanisms. <i>Cancer Research</i> , 2005, 65, 2906-2913.	0.9	87
9	Critical Role of Flanking Residues in NGR-to-isoDGR Transition and CD13/Integrin Receptor Switching. <i>Journal of Biological Chemistry</i> , 2010, 285, 9114-9123.	3.4	77
10	Isoaspartate-Glycine-Arginine: A New Tumor Vasculature-Targeting Motif. <i>Cancer Research</i> , 2008, 68, 7073-7082.	0.9	71
11	Crucial Role for Interferon γ in the Synergism between Tumor Vasculature-Targeted Tumor Necrosis Factor β (NGR-TNF) and Doxorubicin. <i>Cancer Research</i> , 2004, 64, 7150-7155.	0.9	66
12	Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif. <i>Molecular Immunology</i> , 2006, 43, 1509-1518.	2.2	49
13	NGR-tagged nano-gold: A new CD13-selective carrier for cytokine delivery to tumors. <i>Nano Research</i> , 2016, 9, 1393-1408.	10.4	48
14	Synergistic Damage of Tumor Vessels with Ultra Low-Dose Endothelial-Monocyte Activating Polypeptide-II and Neovasculature-Targeted Tumor Necrosis Factor β . <i>Cancer Research</i> , 2008, 68, 1154-1161.	0.9	45
15	Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion. <i>Biomaterials</i> , 2015, 68, 89-99.	11.4	36
16	IsoDGR-tagged Albumin: A New α V β 3 Selective Carrier for Nanodrug Delivery to Tumors. <i>Small</i> , 2013, 9, 673-678.	10.0	33
17	Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFN γ . <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3859-3866.	4.1	25
18	Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients. <i>Cancer Research</i> , 2016, 76, 1781-1791.	0.9	24

#	ARTICLE	IF	CITATIONS
19	Chromogranin A Restricts Drug Penetration and Limits the Ability of NGR-TNF to Enhance Chemotherapeutic Efficacy. <i>Cancer Research</i> , 2011, 71, 5881-5890.	0.9	23
20	Enhancement of Tumor Homing by Chemotherapy-Loaded Nanoparticles. <i>Small</i> , 2018, 14, e1802886.	10.0	23
21	Boosting Interleukin-12 Antitumor Activity and Synergism with Immunotherapy by Targeted Delivery with isoDGR-Tagged Nanogold. <i>Small</i> , 2019, 15, e1903462.	10.0	21
22	Glycine N-Methylation in NGR-Tagged Nanocarriers Prevents Isoaspartate Formation and Integrin Binding without Impairing CD13 Recognition and Tumor Homing. <i>Advanced Functional Materials</i> , 2017, 27, 1701245.	14.9	19
23	Succinimide-Based Conjugates Improve IsoDGR Cyclopeptide Affinity to $\alpha_v\beta_3$ without Promoting Integrin Allosteric Activation. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7474-7485.	6.4	19
24	Regulation of tumor growth by circulating full-length chromogranin A. <i>Oncotarget</i> , 2016, 7, 72716-72732.	1.8	18
25	Effect of chromogranin A-derived vasostatin-1 on laser-induced choroidal neovascularization in the mouse. <i>Acta Ophthalmologica</i> , 2015, 93, e218-22.	1.1	16
26	Enhancement of doxorubicin anti-cancer activity by vascular targeting using IsoDGR/cytokine-coated nanogold. <i>Journal of Nanobiotechnology</i> , 2021, 19, 128.	9.1	13
27	Spatiotemporal Regulation of Tumor Angiogenesis by Circulating Chromogranin A Cleavage and Neuropilin-1 Engagement. <i>Cancer Research</i> , 2019, 79, 1925-1937.	0.9	9
28	Biotinylation Sites of Tumor Necrosis Factor- β Determined by Liquid Chromatography-Mass Spectrometry. <i>Analytical Biochemistry</i> , 2001, 298, 181-188.	2.4	8
29	Characterisation of functional biotinylated TNF- β targeted to the membrane of apoptotic melanoma cells. <i>Journal of Immunological Methods</i> , 2003, 276, 79-87.	1.4	6
30	NGR-TNF Engineering with an N-Terminal Serine Reduces Degradation and Post-Translational Modifications and Improves Its Tumor-Targeting Activity. <i>Molecular Pharmaceutics</i> , 2020, 17, 3813-3824.	4.6	6
31	A stapled chromogranin A-derived peptide is a potent dual ligand for integrins $\alpha_v\beta_6$ and $\alpha_v\beta_8$. <i>Chemical Communications</i> , 2019, 55, 14777-14780.	4.1	5
32	Nanogold Functionalized With Lipoamide-isoDGR: A Simple, Robust and Versatile Nanosystem for $\alpha_v\beta_3$ -Integrin Targeting. <i>Frontiers in Chemistry</i> , 2021, 9, 690357.	3.6	2